F
Fotios Loupakis
Researcher at University of Pisa
Publications - 400
Citations - 17324
Fotios Loupakis is an academic researcher from University of Pisa. The author has contributed to research in topics: Colorectal cancer & Bevacizumab. The author has an hindex of 57, co-authored 390 publications receiving 13698 citations. Previous affiliations of Fotios Loupakis include University of Turin & University of Southern California.
Papers
More filters
Journal ArticleDOI
Liquid biopsy: monitoring cancer-genetics in the blood.
TL;DR: This Review will explore how tumour-associated mutations detectable in the blood can be used in the clinic after diagnosis, including the assessment of prognosis, early detection of disease recurrence, and as surrogates for traditional biopsies with the purpose of predicting response to treatments and the development of acquired resistance.
Journal ArticleDOI
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
Giulia Siravegna,Benedetta Mussolin,Michela Buscarino,Giorgio Corti,Andrea Cassingena,Giovanni Crisafulli,Agostino Ponzetti,Chiara Cremolini,Alessio Amatu,Calogero Lauricella,Simona Lamba,Sebastijan Hobor,Antonio Avallone,Emanuele Valtorta,Giuseppe Rospo,Enzo Medico,Valentina Motta,Carlotta Antoniotti,Fabiana Tatangelo,Beatriz Bellosillo,Silvio Veronese,Alfredo Budillon,Clara Montagut,Patrizia Racca,Silvia Marsoni,Alfredo Falcone,Ryan B. Corcoran,Federica Di Nicolantonio,Fotios Loupakis,Salvatore Siena,Andrea Sartore-Bianchi,Alberto Bardelli +31 more
TL;DR: The results indicate that the CRC genome adapts dynamically to intermittent drug schedules and provide a molecular explanation for the efficacy of rechallenge therapies based on EGFR blockade.
Journal ArticleDOI
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Scott Kopetz,Axel Grothey,Rona Yaeger,Eric Van Cutsem,Jayesh Desai,Takayuki Yoshino,Harpreet Wasan,Fortunato Ciardiello,Fotios Loupakis,Yong Sang Hong,Neeltje Steeghs,Tormod Kyrre Guren,Hendrik Tobias Arkenau,Pilar García-Alfonso,Per Pfeiffer,Sergey Orlov,Sara Lonardi,Elena Elez,Tae Won Kim,Jan H.M. Schellens,Christina Guo,Asha Krishnan,Jeroen Dekervel,Van Morris,Aitana Calvo Ferrándiz,Line Schmidt Tarpgaard,Michael Braun,Ashwin Gollerkeri,Christopher Hunt Keir,Kati Maharry,Michael D Pickard,Janna Christy-Bittel,Lisa Anderson,Victor Sandor,Josep Tabernero +34 more
TL;DR: A combination of encorafenib, cetuximab, and binimetinib resulted in significantly longer overall survival and a higher response rate than standard therapy in patients with metastatic colorectal cancer with the BRAF V600E mutation.
Journal ArticleDOI
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
Chiara Cremolini,Fotios Loupakis,Carlotta Antoniotti,Cristiana Lupi,Elisa Sensi,Sara Lonardi,Silvia Mezi,Gianluca Tomasello,Monica Ronzoni,Alberto Zaniboni,Giuseppe Tonini,Chiara Carlomagno,Giacomo Allegrini,Silvana Chiara,Mauro D'Amico,Cristina Granetto,Marina Cazzaniga,Luca Boni,Gabriella Fontanini,Alfredo Falcone +19 more
TL;DR: An updated analysis of the TRIBE study aimed to provide mature results for overall survival-a secondary endpoint-and report treatment efficacy in RAS and BRAF molecular subgroups, and assessed the secondary endpoint of overall survival in the main cohort.
Journal ArticleDOI
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
Fotios Loupakis,Chiara Cremolini,Gianluca Masi,Sara Lonardi,Vittorina Zagonel,Lisa Salvatore,Enrico Cortesi,Gianluca Tomasello,Monica Ronzoni,Rosella Spadi,Alberto Zaniboni,Giuseppe Tonini,Angela Buonadonna,Domenico Amoroso,Silvana Chiara,Chiara Carlomagno,Corrado Boni,Giacomo Allegrini,Luca Boni,Alfredo Falcone +19 more
TL;DR: FOLFOXIRI plus bevacizumab, as compared with FOLFIRI plus was improved the outcome in patients with metastatic colorectal cancer and increased the incidence of some adverse events.